NO20054790L - Anvendelse av B7-113 som et immunoregulatorisk middel - Google Patents

Anvendelse av B7-113 som et immunoregulatorisk middel

Info

Publication number
NO20054790L
NO20054790L NO20054790A NO20054790A NO20054790L NO 20054790 L NO20054790 L NO 20054790L NO 20054790 A NO20054790 A NO 20054790A NO 20054790 A NO20054790 A NO 20054790A NO 20054790 L NO20054790 L NO 20054790L
Authority
NO
Norway
Prior art keywords
immunology
immunoregulatory agent
modulating
present
vcvc
Prior art date
Application number
NO20054790A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054790D0 (no
Inventor
Mary Collins
Beatriz M Carreno
Vincent Ling
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054790D0 publication Critical patent/NO20054790D0/no
Publication of NO20054790L publication Critical patent/NO20054790L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20054790A 2003-04-17 2005-10-18 Anvendelse av B7-113 som et immunoregulatorisk middel NO20054790L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46334203P 2003-04-17 2003-04-17
PCT/US2004/011767 WO2004093894A2 (en) 2003-04-17 2004-04-16 Use of b7-h3 as an immunoregulatory agent

Publications (2)

Publication Number Publication Date
NO20054790D0 NO20054790D0 (no) 2005-10-18
NO20054790L true NO20054790L (no) 2005-11-16

Family

ID=33310770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054790A NO20054790L (no) 2003-04-17 2005-10-18 Anvendelse av B7-113 som et immunoregulatorisk middel

Country Status (14)

Country Link
US (1) US20050002935A1 (enExample)
EP (1) EP1620119A2 (enExample)
JP (2) JP2006523711A (enExample)
KR (1) KR20060017496A (enExample)
CN (1) CN1809370A (enExample)
AU (1) AU2004231748A1 (enExample)
BR (1) BRPI0409476A (enExample)
CA (1) CA2521847A1 (enExample)
CO (1) CO5700783A2 (enExample)
MX (1) MXPA05011050A (enExample)
NO (1) NO20054790L (enExample)
RU (1) RU2005135739A (enExample)
WO (1) WO2004093894A2 (enExample)
ZA (1) ZA200508367B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
MXPA02012106A (es) 2000-06-06 2003-06-06 Bristol Myers Squibb Co Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
CN101845091A (zh) 2004-06-25 2010-09-29 武田药品工业株式会社 转移素衍生物及其用途
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JP5601836B2 (ja) * 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド Ｔｅｓ７およびｔｅｓ７に結合する抗体
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
PH12013502201A1 (en) * 2011-04-25 2014-01-13 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AU2015217278B2 (en) 2014-02-14 2020-03-19 Macrogenics, Inc. Improved methods for the treatment of vascularizing cancers
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
US10899837B2 (en) * 2017-03-31 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
CN109097366A (zh) * 2017-06-21 2018-12-28 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用
WO2020094120A1 (zh) 2018-11-09 2020-05-14 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN113260703A (zh) * 2018-12-24 2021-08-13 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用
CN118878681A (zh) * 2019-07-18 2024-11-01 泰州复旦张江药业有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法
CN119504997A (zh) 2021-02-09 2025-02-25 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
WO2023155808A1 (zh) 2022-02-16 2023-08-24 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
US20250325688A1 (en) 2022-05-18 2025-10-23 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
CN120898001A (zh) * 2023-01-10 2025-11-04 上海仁又生基因技术有限公司 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012106A (es) * 2000-06-06 2003-06-06 Bristol Myers Squibb Co Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
WO2002010187A1 (en) * 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
US20040236088A1 (en) * 2001-08-02 2004-11-25 Heuer Josef Georg Novel polypeptide analogs and fusions and their methods of use

Also Published As

Publication number Publication date
EP1620119A2 (en) 2006-02-01
CO5700783A2 (es) 2006-11-30
NO20054790D0 (no) 2005-10-18
MXPA05011050A (es) 2006-03-17
WO2004093894A3 (en) 2005-03-24
KR20060017496A (ko) 2006-02-23
CA2521847A1 (en) 2004-11-04
CN1809370A (zh) 2006-07-26
JP2006523711A (ja) 2006-10-19
US20050002935A1 (en) 2005-01-06
AU2004231748A1 (en) 2004-11-04
BRPI0409476A (pt) 2006-05-02
ZA200508367B (en) 2007-04-25
RU2005135739A (ru) 2006-03-20
WO2004093894A8 (en) 2005-05-19
JP2007191489A (ja) 2007-08-02
WO2004093894A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
NO20054790L (no) Anvendelse av B7-113 som et immunoregulatorisk middel
Covre et al. The role of senescent T cells in immunopathology
Schneider et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers
Schwarz et al. Biological activity of masked endotoxin
Lee et al. Heat shock protein (Hsp) 70 is an activator of the Hsp104 motor
Ricart et al. Dendritic cells distinguish individual chemokine signals through CCR7 and CXCR4
Melnyk et al. Peptidoglycan modifications tune the stability and function of the innate immune receptor Nod2
EP1631314A4 (en) METHOD FOR MODIFYING BINDING SPECIFICITY OF PLASMIC PROTEINS USING OXIDATION-REDUCTION REACTIONS
ATE382053T1 (de) System zur antikörperexpression und- synthese
BR0111191A (pt) Moléculas mutantes de ctla4 solúveis e seus usos
ATE330038T1 (de) Nukleinsäure-biosensor
ATE448258T1 (de) Befestigung von molekülen auf oberflächen
CY1117023T1 (el) Διεργασια για την παρασκευη τροποποιημενων ηλεκτροδιων, ηλεκτροδια παρασκευασμενα με την εν λογω διεργασια και ενζυμικοι βιοαισθητηρες που περιλαμβανουν τα εν λογω ηλεκτροδιa
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
Bekeschus et al. Cold physical plasma selects for specific T helper cell subsets with distinct cells surface markers in a caspase‐dependent and NF‐κB‐independent manner
Herweg et al. Interaction of Chlamydiae with human macrophages
ATE530911T1 (de) Bindungsproteine als biosensoren
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
Seya et al. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer
DE60325611D1 (de) Benzoat- und antranilatinduzierbare promotoren
DE60239467D1 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
DE60324687D1 (de) Lektinweg-defizienz-assay
CA2602635C (en) Method of altering the binding specificity of proteins by oxidation-reduction reactions
Dustin Help to go: T cells transfer CD40L to antigen‐presenting B cells
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application